Sibeprenlimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | A proliferation-inducing ligand (TNFSF13) |
| Clinical data | |
| Trade names | Voyxact |
| Other names | VIS-649, sibeprenlimab-szsi |
| AHFS/Drugs.com | voyxact |
| License data | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6488H10002N1744O2013S52 |
| Molar mass | 146310.70 g·mol−1 |
Sibeprenlimab, sold under the brand name Voyxact, is a humanized monoclonal antibody used for the treatment of immunoglobulin A nephropathy. It is an a proliferation-inducing ligand blocker. It is given by injection under the skin (subcutaneous).
The most common side effects include infections (including upper respiratory tract infection) and injection site reactions, including injection site erythema (skin redness).
Sibeprenlimab was approved for medical use in the United States in November 2025.